Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : GUMM - Eliminate the Common Cold -- Ignore unavailable to you. Want to Upgrade?

To: Hank who wrote (1839)	12/7/1999 12:32:00 PM
From: pz	Read Replies (1) \| Respond to of 5582

Hank, Please read this carefully. What part of this are you having trouble comprehending? Paul biz.yahoo.com Gum Tech Announces Withdrawal of Journal Article WOODLAND HILLS, Calif., Nov. 4 /PRNewswire/ -- Gel Tech, a joint venture of Gum Tech, International (Nasdaq: GUMM - news) and Bio Delivery Technologies, announced today that the American Journal of Infection Control (AJIC) is withdrawing the manuscript ''The effect of direct application of ionic zinc nasal spray gel on the duration of the common cold'' from publication. The Journal had planned on using the study in a future issue.

To: Hank who wrote (1839)	12/7/1999 12:35:00 PM
From: pz	Respond to of 5582

Hank, Further the article states.... So the 2nd clinicals are due out anyday. Paul ''This in no way reflects on the positive results or the integrity of the study,'' said Dr. Charles Hensley, scientific affairs director at Gel Tech. The initial internal study found that Zicam significantly reduced the duration of the common cold. Hensley said, ''We are continuing our research on Zicam with a separate large-scale independent clinical study. We expect the results of that study to be announced in the near future and submitted for publication at a later date in compliance with all required protocols.''